Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active:	No
Cancer Type:	Cancer-Related Syndrome Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT04013685
Trial Phases:	Phase I	Protocol IDs:	TRGFT-201 (primary) NCI-2019-08529
Eligibility:	18 - 75 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Orca Biosystems, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04013685

Summary

This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic
stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant
recipient) from the mobilized peripheral blood of a specific, unique donor. It is
composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory
T cells (Tregs), and conventional T cells (Tcons) in participants undergoing
myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic
malignancies.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.